Klein Ronald, Klein Barbara E K, Tomany Sandra C, Danforth Lorraine G, Cruickshanks Karen J
Departments of Ophthalmology and Visual Sciences and Population Health Sciences, University of Wisconsin Medical School, Madison, WI 53726, USA.
Arch Ophthalmol. 2003 Aug;121(8):1151-5. doi: 10.1001/archopht.121.8.1151.
To examine the association of hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) with the 5-year incidence of age-related maculopathy (ARM).
Population-based cohort study. Participants included persons 48 to 91 years old examined March 1, 1993, through June 14, 1995, living in Beaver Dam, Wis (N = 3684), of whom 2780 participated in a follow-up 5 years later.
Standardized procedures were used for physical examinations, blood sample collection, and questionnaire administration. Age-related maculopathy was determined by grading images of the posterior pole using a standard protocol. Standard univariate and multivariate analyses were performed.
Incidence and progression of ARM was measured over the 5-year interval.
While controlling for age and sex, statin use was not found to be associated with the 5-year incidence of early ARM (odds ratio [OR], 1.12; 95% confidence interval [CI], 0.47-2.67), progression of ARM (OR, 1.22; 95% CI, 0.54-2.76), or incidence of late ARM (OR, 0.41; 95% CI, 0.12-1.45).
These findings do not suggest an association between statin use and incident ARM over a 5-year period. Further investigation of these relationships in larger studies over a longer period is needed.
研究羟甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）与年龄相关性黄斑病变（ARM）5年发病率之间的关联。
基于人群的队列研究。参与者包括1993年3月1日至1995年6月14日期间在威斯康星州比弗代尔接受检查的48至91岁人群（N = 3684），其中2780人在5年后参与了随访。
采用标准化程序进行体格检查、采集血样和问卷调查。年龄相关性黄斑病变通过使用标准方案对后极部图像进行分级来确定。进行了标准的单变量和多变量分析。
在5年期间测量ARM的发病率和进展情况。
在控制年龄和性别后，未发现使用他汀类药物与早期ARM的5年发病率（优势比[OR]，1.12；95%置信区间[CI]，0.47 - 2.67）、ARM的进展（OR，1.22；95%CI，0.54 - 2.76）或晚期ARM的发病率（OR，0.41；95%CI，0.12 - 1.45）相关。
这些发现未表明在5年期间使用他汀类药物与新发ARM之间存在关联。需要在更大规模的研究中进行更长时间的进一步调查。
